62 completed, 9 recruiting, 7 terminated, 6 unknown. 39 Phase 1, 33 Phase 3, 8 Phase 2, 4 Phase 4, 2 Not applicable.
Follow Celltrion: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of L03TD1 in Healthy Volunteers L03RD1, L03RD2, L03TD1 - Type 2 Diabetes Mellitus (T2DM) | Phase 1 | Completed | Celltrion | 48 | 2026-05-09 | 2026-07-28 |
| A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P52 in Healthy Male Subjects CT-P52 - Healthy Male Subjects | Phase 1 | Completed | Celltrion | 218 | 2026-01-26 | 2026-07-17 |
| Zymfentra (Infliximab-dyyb) REal World Cohort STudy Ulcerative Colitis (UC), Crohn's Disease (CD) | Recruiting | University of North Carolina, Chapel Hill | 200 | 2025-11-20 | 2026-08-05 | |
| Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects Ixekizumab - Healthy Participants | Phase 1 | Active not recruiting | Celltrion | 218 | 2025-09-17 | 2025-12-31 |
| A Bioequivalence Study of CT-L02 Compared to Co-administration (CTL0201 and CTL0202) in Healthy Volunteers CTL02, CTL0201, CTL0202 - Healthy | Phase 1 | Completed | Celltrion | 40 | 2025-09-17 | 2025-11-17 |
| Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of CT-L03 in Healthy Volunteers L03RD1, L03RD2, CT-L03 - Type 2 Diabetes Mellitus (T2DM) | Phase 1 | Completed | Celltrion | 49 | 2025-08-18 | 2025-11-21 |
| A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma CT-P44(Daratumumab), Darzalex Faspro(Daratumumab) - Refractory or Relapsed Multiple Myeloma | Phase 3 | Active not recruiting | Celltrion | 473 | 2025-08-12 | 2026-10-27 |
| TIDHI Mental Health in IBD Patients Study Healing Circuits™ sessions, self-directed Healing Circuits™ curriculum - Crohn Disease (CD), Ulcerative Colitis (UC) | Not applicable | Recruiting | TIDHI Innovation Inc. | 100 | 2025-07-22 | 2026-09-29 |
| Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin Metformin, Alogliptin, empagliflozin - T2DM, Diabete Type 2 | Phase 3 | Recruiting | Celltrion | 171 | 2025-07-18 | 2025-08-11 |
| A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P43 in Healthy Male Subjects CT-P43 - Healthy Male Subjects | Phase 1 | Completed | Celltrion | 162 | 2025-05-30 | 2026-02-24 |
| A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis CT-P55, EU-approved Cosentyx - Plaque Psoriasis | Phase 3 | Active not recruiting | Celltrion | 153 | 2025-05-26 | 2026-02-23 |
| To Compare the Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous CT-P6 and Herceptin in Healthy Male Subjects (Trastuzumab) CT-P6 SC, EU-Approved Herceptin SC - Healthy | Phase 1 | Completed | Celltrion | 200 | 2025-03-26 | 2026-04-23 |
| A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer CT-P51, EU-approved Keytruda - Non Squamous Non Small Cell Lung Cancer | Phase 3 | Active not recruiting | Celltrion | 225 | 2025-01-30 | 2026-07-08 |
| A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid Arthritis CT-P13 SC Auto-Injector, Placebo Auto-Injector - Moderately to Severely Active Rheumatoid Arthritis | Phase 3 | Completed | Celltrion | 192 | 2025-01-03 | 2026-04-23 |
| Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes Pioglitazone 15 MG [Actos], Empagliflozin 10 MG [Jardiance], Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos] - Type 2 Diabetes, Fatty Liver | Phase 4 | Recruiting | Seoul National University Bundang Hospital | 120 | 2025-01-01 | 2025-05-25 |
| A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH) Dual-combination therapy, Triple-combination therapy, Dexcom G7, Pasta - Type 2 Diabetes | Not applicable | Recruiting | Kyu Chang Won | 5950 | 2024-11-21 | 2025-04-24 |
| Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin CT-L03 Group 1, CT-L03 Group 2, Placebo - T2DM | Phase 3 | Completed | Celltrion | 606 | 2024-08-27 | 2026-05-15 |
| Subcutaneous Infliximab After A Previous Intravenous Dose Optimization Infliximab - Inflammatory Bowel Diseases, Crohn Disease | Phase 4 | Recruiting | Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW | 275 | 2024-04-09 | 2024-07-26 |
| To Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55 and Cosentyx in Healthy Subjects CT-P55, US-licensed Cosentyx, EU-approved Cosentyx - Healthy Male Subjects | Phase 1 | Completed | Celltrion | 172 | 2024-01-12 | 2025-07-08 |
| A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis CT-P53, US-Ocrevus, EU-Ocrevus - Relapsing-remitting Multiple Sclerosis | Phase 3 | Recruiting | Celltrion | 512 | 2024-01-11 | 2024-05-22 |
Showing 20 of 90. Sign in to see all of them.
Arthritis, Rheumatoid (13) · Crohn Disease (9) · Colitis, Ulcerative (7) · COVID-19 (6) · Diabetes Mellitus, Type 2 (5) · Inflammatory Bowel Diseases (4) · Spondylitis, Ankylosing (4) · Breast Neoplasms (2) · Essential Hypertension (2) · Lymphoma, Follicular (2) · Psoriasis (2) · Adenocarcinoma of Lung (1) · Arthritis, Psoriatic (1) · Cardiomyopathy, Hypertrophic (1) · Chronic Urticaria (1)
Infliximab (12) · Rituximab (8) · CT-P13 (6) · Trastuzumab (5) · CT-P10 (3) · CT-P17 (3) · Methotrexate (3) · empagliflozin (3) · regdanvimab (3) · Bevacizumab (2) · CT-P6 (2) · CT-P63 (2) · Folic Acid (2) · Metformin (2) · Paclitaxel (2)
South Korea (48) · Poland (12) · United States (7) · France (5) · Estonia (3) · Japan (3) · Latvia (3) · Ukraine (3) · Australia (2) · Belarus (2) · Bulgaria (2) · Georgia (2) · Germany (2) · Hungary (2) · India (2)
MinJi Ma (3) · MoonSun Choi (3) · Investigational Site (2) · Klara Sirova (2) · KyungSang Yu (2) · Minji Ma (2) · SuEun Song (2) · SungHyun Kim (2) · Won Park, M.D., Ph.D. (2) · Andreas Stallmach, Prof. Dr. med. (1) · Annick Moens, MD, PhD (1) · Dae Hyun Yoo (1) · Dae Hyun Yoo, M.D., Ph.D. (1) · DaeHyun Yoo, M.D., Ph.D (1) · DaeHyun Yoo, M.D., Ph.D. (1)
PMID 34250583, PMID 34473343, PMID 32905628, PMID 34551869, PMID 35713300, PMID 38788861, PMID 40243842, PMID 41849243, PMID 41986154, PMID 42542998, PMID 23687260, PMID 26795209, PMID 27038608, PMID 27117698, PMID 27130908, PMID 27624791, PMID 28592386, PMID 28600696, PMID 28612179, PMID 28712940, PMID 29411318, PMID 30010481, PMID 30389036, PMID 30719632, PMID 30850957, PMID 30929895, PMID 31184752, PMID 31428820, PMID 33230526, PMID 33245751, PMID 33503313, PMID 33546755, PMID 33676969, PMID 33822406, PMID 34142111, PMID 34148205, PMID 34216825, PMID 34477816, PMID 34686445, PMID 35295819, PMID 35435862, PMID 36043180, PMID 36056419, PMID 36169807, PMID 36534825, PMID 37004656, PMID 37231670, PMID 37991693, PMID 38349618, PMID 38365502
2019 (3), 2016 (2), 2018 (1)